Treace John T. 4

What Happened

• John T. Treace, CEO of Treace Medical Concepts, Inc. (TMCI), received a grant of 250,000 restricted stock units (RSUs) on 2026-01-22 (transaction code A). The Form 4 also shows 14,254 shares disposed on the same date under a tax withholding/settlement (transaction code F) — these shares were surrendered to satisfy tax withholding obligations. Both items report $0 cash paid/received on the filing (typical for RSU grants and share withholding).

Key Details

• Transaction dates: 2026-01-22 (report filed 2026-01-23).
• Grant: 250,000 RSUs (code A) — reported acquisition at $0.
• Withholding: 14,254 shares surrendered (code F) to cover tax liability — reported as disposed at $0.
• Vesting: Footnote F2 states the RSUs vest in equal annual installments over 4 years, with first vesting on Jan 22, 2027 and final vesting on Jan 22, 2030, contingent on continued service.
• Other footnotes: F1/F3 reference holdings that include 321,871 and 571,871 RSUs (as noted in the filing); F4 and F5 disclaim beneficial ownership of certain shares held by spouse or trusts for which the reporting person is trustee/co-trustee.
• Timeliness: Filing was submitted the next day (no late filing indicated).

Context

• This was a compensation award (RSUs), not an open-market purchase or sale by the CEO. RSU grants are common as executive compensation and vest over time, so they do not necessarily signal immediate bullish buying by the insider.
• The 14,254-share disposition reflects tax withholding on the grant (a routine administrative step), not a market sale for investment reasons.